ストックスクリーナーアプリを入手
33.69
1.94%
0.64
プレマーケット:
34.50
0.81
+2.40%
Galapagos Nv Adr (GLPG) 最新ニュース
Galapagos FY 2025 slides: €3B cash fuels transformation strategy - Investing.com Australia
RBC Capital raises Galapagos stock price target to $33 on model updates - Investing.com South Africa
Earnings call transcript: Galapagos Q4 2025 earnings surpass expectations, stock rises By Investing.com - Investing.com South Africa
Galapagos stock rating reiterated at Market Perform by Raymond James - Investing.com
Galapagos FY 2025 slides: €3B cash fuels transformation strategy By Investing.com - Investing.com South Africa
Earnings call transcript: Galapagos Q4 2025 earnings surpass expectations, stock rises - Investing.com
Earnings Breakdown: Galapagos Q4 - Sahm
A Peek at Galapagos's Future Earnings - Sahm
Stock Market Today: Nasdaq Futures Pare Losses, Dow Drops After Scaling Record Highs— CoreWeave, Vistra, Microchip Technology In Focus (UPDATED) - Benzinga
Stock Market Today: Nasdaq Futures Pare Losses, Dow Drops After Scaling Record Highs— CoreWeave, Vistra, Microchip Technology In Focus (UPDATED) - Benzinga
Stock Market Today: Dow Jones Futures Drop After Scaling Record Highs— CoreWeave, Vistra, Microchip Technology In Focus - Sahm
AngioDynamics, Microchip Technology And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Galapagos NV (NASDAQ:GLPG) Given Average Rating of “Reduce” by Analysts - Defense World
Galapagos stock holds steady as Raymond James maintains Market Perform rating By Investing.com - Investing.com South Africa
Galapagos stock holds steady as Raymond James maintains Market Perform rating - Investing.com
Bernstein initiates Market Perform rating on Galapagos stock with EUR27.90 target - Investing.com
Galapagos NV (GLPG) Stock Price, Trades & News - GuruFocus
Operating cash flow per share of Galapagos NV Sponsored ADR – NASDAQ:GLPG - TradingView
Working capital per share of Galapagos NV Sponsored ADR – NASDAQ:GLPG - TradingView
Galapagos NV (NASDAQ:GLPG) Receives Average Rating of “Reduce” from Analysts - Defense World
EBIT per share of Galapagos NV Sponsored ADR – NASDAQ:GLPG - TradingView
Earnings call transcript: Galapagos Q3 2025 sees earnings miss, stock steady By Investing.com - Investing.com Canada
Earnings call transcript: Galapagos Q3 2025 sees earnings miss, stock steady - Investing.com
Galapagos stock price target raised to $28 from $27 at RBC Capital - Investing.com
Galapagos stock rating upgraded by Leerink Partners on cost-cutting moves - Investing.com
PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Galapagos Appoints Fred Blakeslee as General Counsel - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), Pharvaris (PHVS) and Stevanato Group (STVN) - The Globe and Mail
How Have Insiders Been Trading Winmark Corporation (WINA) Stock? - fostersleader.com
Why You Need Galapagos NV ADR (GLPG) On Your Watchlist - fostersleader.com
Stock on Demand This Week: Hour Loop Inc (HOUR) - fostersleader.com
MasterCraft Boat Holdings Inc (MCFT): What the Financials Tell Us - fostersleader.com
Is Buying Stock In Radiopharm Theranostics Ltd ADR (RADX) A Good Move Today? - fostersleader.com
Major Brokerage Firms Issue Research Notes on Surgepays Inc (SURG) - fostersleader.com
Vishay Precision Group Inc (VPG) Shares: Cheap or Risky? - fostersleader.com
Clene Inc (CLNN): What Technical Indicators Show - fostersleader.com
SolarMax Technology Inc (SMXT): What Does Valuation Ratios Tell Us? - fostersleader.com
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real? - TechStock²
Galapagos Updates on Cell Therapy Business Strategic Review - The Globe and Mail
Galapagos NV (GLPG)' CAR-T Therapy Hits 97% Response Rate in Lymphoma Trial - Finviz
Galapagos (0JXZ) was downgraded to a Sell Rating at Deutsche Bank - The Globe and Mail
Galapagos NV Reports Strong H1 2025 Results Amid Strategic Transformation - The Globe and Mail
Raymond James reiterates Market Perform rating on Galapagos stock - Investing.com
Galapagos ADR earnings missed by $0.05, revenue topped estimates - Investing.com
Galapagos stock holds as CEO change, spinoff plans halted - Investing.com
Galapagos stock holds Market Perform rating at Raymond James - Investing.com
Galapagos To Spin Off Innovative Medicines Business - Forbes
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies - Investing.com
Earnings call: Galapagos focuses on oncology and immunology in H1 2024 report - Investing.com
Galapagos NV shares poised for outperformance, says TD Cowen - Investing.com
Adaptimmune and Galapagos partner on cancer therapy - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Billionaire hedge fund manager David Einhorn’s portfolio revealed - Daily Investor
GLPG Stock Price and Chart — EURONEXT:GLPG - TradingView — Track All Markets
Galapagos Surges On New CEO and Upgrade News - Investing.com
The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs - Yahoo Finance
The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology - Yahoo Finance
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):